ClinicalTrials.gg
CompletedNCT06180967Updated Feb 24, 2025Results posted

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants

A Phase 1 interventional study of Midazolam Syrup and Midazolam Solution in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Sep 2020, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. The study will also access how much endogenous coproporphyrins I and III as biomarkers of OATP1B1 and OATP1B3 is in the bloodstream and how the body handles and eliminates them following single and multiple oral doses of Pirtobrutinib. Safety and tolerability of Pirtobrutinib will also be evaluated. For each participant, the total duration of the study will be 59 days, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
  • Male and female participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator
  • Female participants of non- and male participants who follow standard methods
  • Must have comply with all study procedures, including the 8-night stay at the Clinical Research Unit (CRU) and follow-up phone call

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Positive serologic test for surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, virus (HCV) antibody, or (HIV) antibody at Screening
  • Positive polymerase chain reaction (PCR) test for COVID-19 at Screening or Check-in (Day -1)
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)
  • Have previously completed or withdrawn from any other study investigating Pirtobrutinib (LOXO-305) and have previously received the product
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Midazolam (Intravenous [IV] Bolus)

    A single IV bolus dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 1 and Day 15.

    Drug: Midazolam Solution

  • Experimental
    Midazolam Oral

    A single oral dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 3 and Day 17.

    Drug: Midazolam Syrup

  • Experimental
    Pirtobrutinib

    Multiple oral doses of Pirtobrutinib once a day (QD) will be administered on Days 5 through Day 17.

    Drug: Pirtobrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-hydroxymidazolam (1-OH-midazolam) Following Oral Dose Administration

    PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  2. PK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

    PK: AUC(0-inf) of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  3. PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

    PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  4. PK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

    PK: Cmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  5. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

    PK: tmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  6. PK: Apparent Terminal Elimination Rate Constant (Lambda [λ] z) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

    PK: λz of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  7. PK: Apparent Systemic Clearance (CL/F) of Midazolam Following Oral Dose Administration

    PK: CL/F of midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  8. PK: Apparent Volume of Distribution (Vz/F) of Midazolam Following Oral Dose Administration

    PK: Vz/F of midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  9. PK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

    PK: t½ of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

    Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  10. PK: Total Clearance (CL) of Midazolam Following Intravenous Dose Administration

    PK: CL of midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  11. PK: Volume of Distribution (Vz) of Midazolam Following Intravenous Dose Administration

    PK: Vz of midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  12. PK: Volume of Distribution at Steady State (Vss) of Midazolam Following Intravenous Dose Administration

    PK: Vss of midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  13. PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

    PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  14. PK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

    PK: AUC0-inf of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  15. PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

    PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  16. PK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

    PK: Cmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  17. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

    PK: tmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  18. PK: Apparent Terminal Elimination Rate Constant (λz) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

    PK: λz of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

  19. PK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

    PK: t1/2 of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

    Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)

Secondary outcomes

  1. PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

    PK: AUC0-t of Pirtobrutinib was reported.

    Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)

  2. PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib

    PK: AUCtau of Pirtobrutinib was reported.

    Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)

  3. PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib

    PK: Cmax of Pirtobrutinib was reported.

    Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)

  4. PK: Concentration Observed at the End Of the Dosing Interval (Ctrough) of Pirtobrutinib

    PK: Ctrough of Pirtobrutinib before multiple oral doses administration was reported.

    Time frame: Period 2: 24-hour post-dose on Day 14, Day 15, and Day 17

  5. PK: Time To Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

    PK: tmax of Pirtobrutinib was reported.

    Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)

  6. PK: Apparent Systemic Plasma Clearance at Steady State (CL,ss/F) of Pirtobrutinib

    PK: CL,ss/F of Pirtobrutinib was reported.

    Time frame: Period 2: Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)

  7. PK: Accumulation Ratio (RAUC) of Pirtobrutinib

    RAUC was ratio of Day 14 AUCtau to Day 5 AUCtau.

    Time frame: Period 2: Day 5 and Day 14 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose)

07

Results

Posted Feb 24, 2025

Participant flow

Period 1: Day 1 to Day 4
Participant flow — Period 1: Day 1 to Day 4
MilestonePeriod 1: All Participants: Midazolam (IV + Oral Dose)Period 2: All Participants: Pirtobrutinib + Midazolam (IV + Oral Dose)
Started150
Received at least 1 dose of study drug150
Completed150
Not completed00
Period 2: Day 5 to Day 20
Participant flow — Period 2: Day 5 to Day 20
MilestonePeriod 1: All Participants: Midazolam (IV + Oral Dose)Period 2: All Participants: Pirtobrutinib + Midazolam (IV + Oral Dose)
Started015
Received at least 1 dose of study drug015
Completed015
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-hydroxymidazolam (1-OH-midazolam) Following Oral Dose Administration

PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · Hours*nanograms per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-hydroxymidazolam (1-OH-midazolam) Following Oral Dose Administration
Hours*nanograms per milliliter (h*ng/mL)Period 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
Midazolam4.81 ± 40.88.30 ± 43.2
Metabolite: 1-OH-medazolam2.24 ± 41.92.52 ± 40.6
PrimaryPK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

PK: AUC(0-inf) of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
h*ng/mLPeriod 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
Midazolam5.31 ± 43.19.01 ± 44.0
Metabolite: 1-OH-midazolam2.60 ± 39.92.92 ± 42.2
PrimaryPK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · percentage of AUC0-inf
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
percentage of AUC0-infPeriod 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
Midazolam8.84 ± 33.77.42 ± 35.3
Metabolite: 1-OH-midazolam12.9 ± 37.512.2 ± 48.6
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

PK: Cmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
nanograms per milliliter (ng/mL)Period 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
Midazolam2.33 ± 36.73.68 ± 34.3
Metabolite: 1-OH-midazolam1.25 ± 42.21.41 ± 40.2
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

PK: tmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Median · Hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
HoursPeriod 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
Midazolam0.750 (0.500 to 1.00)0.500 (0.500 to 0.750)
Metabolite: 1-OH-midazolam0.750 (0.500 to 1.00)0.500 (0.500 to 1.00)
PrimaryPK: Apparent Terminal Elimination Rate Constant (Lambda [λ] z) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

PK: λz of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · one per hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (Lambda [λ] z) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
one per hour (1/h)Period 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
Midazolam0.316 ± 50.70.227 ± 50.2
Metabolite: 1-OH-midazolam0.441 ± 35.40.419 ± 61.2
PrimaryPK: Apparent Systemic Clearance (CL/F) of Midazolam Following Oral Dose Administration

PK: CL/F of midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · Liters per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Midazolam Following Oral Dose Administration
Liters per hour (L/h)Period 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Apparent Systemic Clearance (CL/F) of Midazolam Following Oral Dose Administration94.2 ± 43.155.5 ± 44.0
PrimaryPK: Apparent Volume of Distribution (Vz/F) of Midazolam Following Oral Dose Administration

PK: Vz/F of midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · Liters
PK: Apparent Volume of Distribution (Vz/F) of Midazolam Following Oral Dose Administration
LitersPeriod 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Apparent Volume of Distribution (Vz/F) of Midazolam Following Oral Dose Administration298 ± 29.7244 ± 29.6
PrimaryPK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration

PK: t½ of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.

Time frame:
Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · hours
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
hoursPeriod 1: Oral Midazolam 500 mcg (Day 3)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
Midazolam2.20 ± 50.73.05 ± 50.2
Metabolite: 1-OH-midazolam1.57 ± 35.41.65 ± 61.2
PrimaryPK: Total Clearance (CL) of Midazolam Following Intravenous Dose Administration

PK: CL of midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · L/h
PK: Total Clearance (CL) of Midazolam Following Intravenous Dose Administration
L/hPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
PK: Total Clearance (CL) of Midazolam Following Intravenous Dose Administration26.0 ± 21.423.1 ± 26.5
PrimaryPK: Volume of Distribution (Vz) of Midazolam Following Intravenous Dose Administration

PK: Vz of midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · Liters
PK: Volume of Distribution (Vz) of Midazolam Following Intravenous Dose Administration
LitersPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
PK: Volume of Distribution (Vz) of Midazolam Following Intravenous Dose Administration113 ± 34.2105 ± 37.8
PrimaryPK: Volume of Distribution at Steady State (Vss) of Midazolam Following Intravenous Dose Administration

PK: Vss of midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · Liters
PK: Volume of Distribution at Steady State (Vss) of Midazolam Following Intravenous Dose Administration
LitersPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
PK: Volume of Distribution at Steady State (Vss) of Midazolam Following Intravenous Dose Administration78.2 ± 29.476.1 ± 31.0
PrimaryPK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
h*ng/mLPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
Midazolam8.89 ± 21.610.1 ± 25.1
Metabolite: 1-OH-medazolam1.39 ± 41.71.21 ± 35.7
PrimaryPK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

PK: AUC0-inf of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
h*ng/mLPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
Midazolam9.62 ± 21.410.8 ± 26.5
Metabolite: 1-OH-medazolam2.13 ± 43.01.62 ± 25.2
PrimaryPK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · percentage of AUC0-inf
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
percentage of AUC0-infPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
Midazolam7.13 ± 37.16.44 ± 42.0
Metabolite: 1-OH-medazolam19.6 ± 24.724.7 ± 11.5
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

PK: Cmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
ng/mLPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
Midazolam6.96 ± 34.86.91 ± 27.8
Metabolite: 1-OH-medazolam0.512 ± 31.70.475 ± 28.6
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

PK: tmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Median · hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
hoursPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
Midazolam0.0833 (0.0833 to 0.250)0.0833 (0.0833 to 0.0833)
Metabolite: 1-OH-medazolam0.750 (0.500 to 1.00)0.750 (0.500 to 1.00)
PrimaryPK: Apparent Terminal Elimination Rate Constant (λz) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

PK: λz of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · 1/h
PK: Apparent Terminal Elimination Rate Constant (λz) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
1/hPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
Midazolam0.229 ± 37.00.221 ± 49.5
Metabolite: 1-OH-medazolam0.224 ± 55.70.282 ± 47.8
PrimaryPK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration

PK: t1/2 of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.

Time frame:
Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
Reported as:
Geometric mean · hours
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
hoursPeriod 1: IV Midazolam 250 mcg (Day 1)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)
Midazolam3.02 ± 37.03.13 ± 49.5
Metabolite: 1-OH-medazolam3.09 ± 55.72.46 ± 47.8
SecondaryPK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

PK: AUC0-t of Pirtobrutinib was reported.

Time frame:
Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
h*ng/mLPeriod 2: Pirtobrutinib 200 mg (Day 5)Period 2: Pirtobrutinib 200 mg (Day 14)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib54800 ± 20.0114000 ± 26.0115000 ± 25.0211000 ± 33.8
SecondaryPK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib

PK: AUCtau of Pirtobrutinib was reported.

Time frame:
Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib
h*ng/mLPeriod 2: Pirtobrutinib 200 mg (Day 5)Period 2: Pirtobrutinib 200 mg (Day 14)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib55000 ± 20.0114000 ± 26.1116000 ± 25.0118000 ± 25.5
SecondaryPK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib

PK: Cmax of Pirtobrutinib was reported.

Time frame:
Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib
ng/mLPeriod 2: Pirtobrutinib 200 mg (Day 5)Period 2: Pirtobrutinib 200 mg (Day 14)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib4880 ± 18.58120 ± 27.18620 ± 23.18750 ± 27.2
SecondaryPK: Concentration Observed at the End Of the Dosing Interval (Ctrough) of Pirtobrutinib

PK: Ctrough of Pirtobrutinib before multiple oral doses administration was reported.

Time frame:
Period 2: 24-hour post-dose on Day 14, Day 15, and Day 17
Reported as:
Geometric mean · ng/mL
PK: Concentration Observed at the End Of the Dosing Interval (Ctrough) of Pirtobrutinib
ng/mLPeriod 2: Pirtobrutinib 200 mg (Day 14)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Concentration Observed at the End Of the Dosing Interval (Ctrough) of Pirtobrutinib3060 ± 32.13180 ± 36.43050 ± 32.7
SecondaryPK: Time To Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

PK: tmax of Pirtobrutinib was reported.

Time frame:
Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
Reported as:
Median · hours
PK: Time To Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
hoursPeriod 2: Pirtobrutinib 200 mg (Day 5)Period 2: Pirtobrutinib 200 mg (Day 14)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Time To Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib2.50 (1.00 to 4.00)3.00 (2.00 to 4.00)3.00 (0.750 to 6.00)3.00 (1.00 to 4.00)
SecondaryPK: Apparent Systemic Plasma Clearance at Steady State (CL,ss/F) of Pirtobrutinib

PK: CL,ss/F of Pirtobrutinib was reported.

Time frame:
Period 2: Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
Reported as:
Geometric mean · L/h
PK: Apparent Systemic Plasma Clearance at Steady State (CL,ss/F) of Pirtobrutinib
L/hPeriod 2: Pirtobrutinib 200 mg (Day 14)Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15)Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17)
PK: Apparent Systemic Plasma Clearance at Steady State (CL,ss/F) of Pirtobrutinib1.75 ± 26.11.72 ± 25.01.69 ± 25.5
SecondaryPK: Accumulation Ratio (RAUC) of Pirtobrutinib

RAUC was ratio of Day 14 AUCtau to Day 5 AUCtau.

Time frame:
Period 2: Day 5 and Day 14 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose)
Reported as:
Geometric mean · Ratio
PK: Accumulation Ratio (RAUC) of Pirtobrutinib
RatioPeriod 2: Pirtobrutinib 200 mg
PK: Accumulation Ratio (RAUC) of Pirtobrutinib2.08 ± 15.9

Adverse events

Collected over From Day 1 up to 7 days post end of treatment (i.e., up to Day 30). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: IV Midazolam 250 mcg0/15 (0%)0/15 (0%)1/15 (6.7%)
Period 1: Oral Midazolam 500 mcg0/15 (0%)0/15 (0%)0/15 (0%)
Period 2: Pirtobrutinib 200 mg0/15 (0%)0/15 (0%)3/15 (20%)
Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg0/15 (0%)0/15 (0%)1/15 (6.7%)
Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg0/15 (0%)0/15 (0%)0/15 (0%)
Most frequent other events
Most frequent other events
EventPeriod 1: IV Midazolam 250 mcgPeriod 1: Oral Midazolam 500 mcgPeriod 2: Pirtobrutinib 200 mgPeriod 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcgPeriod 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg
ConstipationGastrointestinal disorders0/150/151/150/150/15
FlatulenceGastrointestinal disorders0/150/151/150/150/15
Injection site painGeneral disorders1/150/150/150/150/15
Pain in extremityMusculoskeletal and connective tissue disorders0/150/150/151/150/15
PollakiuriaRenal and urinary disorders0/150/151/150/150/15
Nasal congestionRespiratory, thoracic and mediastinal disorders0/150/151/150/150/15
RashSkin and subcutaneous tissue disorders0/150/151/150/150/15

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib
Mean33.9 ± 9.50
Sex: Female, Male
Sex: Female, Male(Participants)All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib
Female3
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib
Hispanic or Latino7
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White10
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib
United States15
08

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Oct 2020, 1 month.

Results were first posted in Feb 2025, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Sep 3, 2020
Primary completionActual
Oct 20, 2020
CompletionActual
Oct 20, 2020
Results first posted
Feb 24, 2025
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06180967
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Sep 3, 2020
Primary completion
Oct 20, 2020
Completion
Oct 20, 2020
Results posted
Feb 24, 2025
Last update
Feb 24, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Midazolam · Pirtobrutinib

Start the discussion